---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Place in treatment, anticipated use, and care setting. Topics: Current US treatment patterns, Care setting for current infused and injected therapies, Company positioning of claseprubart in CIDP, Company-sponsored survey of US neurologists on unmet need, and 8 further topics. 13 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary

In a US claims analysis of 3,409 individuals with CIDP, 2,758 (81%) were treated during the first year, and steroids (73% of those treated) followed by immunoglobulin (65%) were the most commonly used treatments. Neurology specialists are the most frequent prescribers of immunoglobulin, which may be given in a hospital clinic, physician's office, infusion clinic, or at home; the Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) prefilled syringe may be administered subcutaneously by patients or caregivers after proper instruction, and the vial is to be administered by a healthcare professional only.

The company positions claseprubart as a potential first-line biologic given as a subcutaneous, infrequently dosed, self-administered injection, and CAPTIVATE enrolls standard-of-care-refractory, standard-of-care-treated, and standard-of-care-naive patients without requiring immunoglobulin withdrawal. Other complement inhibitors are in development: Sanofi announced that the phase 3 MOBILIZE trial of riliprubart, an antibody that selectively inhibits activated C1s, in CIDP refractory to standard-of-care treatment will be stopped after an independent data monitoring committee determined at an interim analysis that it is unlikely to provide sufficient efficacy, and that continuation of VITALIZE will be evaluated accordingly; argenx is advancing two phase 3 trials of empasiprubart, an antibody targeting C2, one of them a head-to-head comparison with intravenous immunoglobulin.

Source: [Blein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12896209/); [Guptill et al. (2024)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/136957); [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/); [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf); [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1); [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9); [Sanofi (2026)](https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-10-05-00-00-3309444); [argenx annual report (2026)](https://reports.argenx.com/2025/argenx-group/our-products-and-product-candidates/empasiprubart-development.html)

<a id="topic-2.2.2.2-2"></a>

### Current US treatment patterns

> “Among patients who received treatment in 2023, a majority in both cohorts received steroids, followed by immunoglobulin.”
> “Patients in both cohorts were most frequently seen by neurology specialists, and these specialists were the most frequent prescribers of immunoglobulin.”

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/)

> “Among 3,409 patients with CIDP identified, the majority (81% [ n = 2,758]) were treated for CIDP while 19% ( n = 651) were untreated for CIDP during 1-year post-index. Steroids (73% [ n = 2017]) followed by Ig (65% [ n = 1,803]) were most commonly utilized.”

Source: [Blein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12896209/)

> “Of the 525 patients identified with newly diagnosed CIDP, 55.2% of patients were prescribed only steroid therapy, and 25.3% of patients were prescribed an IVIG therapy during the 2-year follow-up.”

Source: [Guptill et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6611518/)

<a id="topic-2.2.2.2-3"></a>

### Care setting for current infused and injected therapies

> “Immunoglobulin may be administered at a hospital clinic, physician’s office, free-standing infusion clinic, or at home with proper monitoring”

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/)

> “When the costs were evaluated by site of care, home infusion visits were a primary site of care in CIDP-specific costs for the patients receiving IVIG.”

Source: [Guptill et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6611518/)

> “VYVGART HYTRULO prefilled syringe may be administered by patients and/or caregivers after proper instruction in subcutaneous injection technique”
> “VYVGART HYTRULO vial is to be administered with a winged infusion set by a healthcare professional only”

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

<a id="topic-2.2.2.2-4"></a>

### Company positioning of claseprubart in CIDP

> “Despite treatment, a significant number of patients do not achieve clinical remission and there remains a significant unmet clinical need for this disease. Given the role of the complement system in the disease pathology, patients may benefit from a selective C1s inhibitor.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “Claseprubart has opportunity to compete as a potential 1L biologic in three large and growing US neuromuscular markets”
> “Opportunity for an active C1s inhibitor with the target profile of claseprubart to replace the standard of care Note: Positioning of claseprubart’s target profile is illustrative.”
> “Improvement over SoC (i.e. Ig) with continuous, effective symptom control”
> “Enrolling a broad patient population including SoC- refractory patients, in addition to SoC-Treated and SoC-Naïve patients”
> “No requirement for IVIg withdrawal and disease worsening, consistent with ongoing FcRn and complement CIDP studies”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “Claseprubart is designed to enable a more convenient SC, infrequently dosed, self-administered injection.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-2.2.2.2-5"></a>

### Company-sponsored survey of US neurologists on unmet need

> “Significant unmet need for effective therapies for patients who don’t respond to IVIg75%”
> “IVIg imposes a high treatment burden due to frequent and time-consuming infusions59%”
> “Overall, surveyed Neurologists believe ~50% of patients on IVIg have partial or no response to treatment”
> “Dianthus 2026 Neurologist CIDP and MMN quantitative survey (n=80, N = 65 Neuromuscular specialists, N = 15 General Neurologists), fielded Q1.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.2.2.2-6"></a>

### Investigational complement inhibitors in CIDP

> “Several complement inhibitors are in development for the treatment of CIDP and increasing evidence suggests that activation of the classical complement pathway plays a crucial role in the pathophysiology of CIDP.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-2.2.2.2-7"></a>

### Riliprubart phase 3 trials: refractory and immunoglobulin-treated populations

> “MOBILIZE, a randomized, double-blind, placebo-controlled trial, targets participants who are presently not on intravenous immunoglobulin (IVIg), and have a history of no/inadequate response to IVIg/corticosteroids.”
> “VITALIZE, a randomized, double-blind, double-dummy, non-inferiority, and superiority design trial with sample size re-estimation will compare riliprubart versus IVIg continuation in IVIg-treated participants, who do not have complete response (i.e. residual disability, even if “stable” on IVIg).”

Source: [Sommer et al. (2026)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-002025.html)

<a id="topic-2.2.2.2-8"></a>

### Riliprubart MOBILIZE trial stopped for insufficient efficacy

> “Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical study identifier: NCT06290128) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment will be stopped.”
> “This decision follows an interim analysis by an independent data monitoring committee, which determined that the MOBILIZE study is unlikely to provide sufficient efficacy. No safety signals related to riliprubart were identified as part of this interim analysis.”
> “The continuation of other ongoing studies with riliprubart, including the VITALIZE phase 3 study (clinical study identifier: NCT06290141) in IVIg-treated patients with CIDP, will be evaluated accordingly.”

Source: [Sanofi (2026)](https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-10-05-00-00-3309444)

<a id="topic-2.2.2.2-9"></a>

### Empasiprubart phase 3 trials

> “argenx is advancing two Phase 3 clinical trials of empasiprubart in CIDP: EMVIGORATE and EMNERGIZE. EMVIGORATE is a head‑to‑head clinical trial comparing empasiprubart to IVIg in adults with CIDP. EMNERGIZE is a randomized, placebo‑controlled clinical trial evaluating the efficacy and safety of empasiprubart. Topline results from both EMVIGORATE and EMNERGIZE are expected in the second half of 2027.”
> “empasiprubart is a differentiated therapeutic mAb targeting C2 equipped with our proprietary NHANCE™ mutations.”

Source: [argenx annual report (2026)](https://reports.argenx.com/2025/argenx-group/our-products-and-product-candidates/empasiprubart-development.html)

<a id="topic-2.2.2.2-10"></a>

### Riliprubart MOBILIZE: refractory population, enrollment, and status in the registry record

> “The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care.”
> “Participant must be refractory to either immunoglobulin therapy or corticosteroid therapy, as defined below.”
> “Immunoglobulin-refractory subgroup: Historic evidence of failure or inadequate response to immunoglobulin therapy prior to screening”
> “Corticosteroid-refractory subgroup: Historic evidence of failure or inadequate response to corticosteroid therapy prior to screening”
> “Primary Completion (Actual) 2026-06-10”
> “Enrollment (Actual) 109”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT06290128](https://clinicaltrials.gov/study/NCT06290128)

<a id="topic-2.2.2.2-11"></a>

### Riliprubart VITALIZE: population maintained on intravenous immunoglobulin in the registry record

> “The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg.”
> “Participants must have responded to IVIg in the past 5 years.”
> “Participant must be on a stable maintenance dosage of IVIg.”
> “Participants receiving IVIg infusions at home are eligible, as long as IVIg infusions are switched to a hospital or infusion center setting at least 1 cycle prior to baseline.”
> “Enrollment (Estimated) 160”

Source: [ClinicalTrials.gov NCT06290141](https://clinicaltrials.gov/study/NCT06290141)

<a id="topic-2.2.2.2-12"></a>

### Empasiprubart EMNERGIZE: untreated and treated participants switching to study drug in the registry record

> “Has not received previous treatment for CIDP; or has stopped receiving CIDP treatment; or is receiving CIDP treatment (pulsed or oral corticosteroids, immunoglobulins, PLEX, or FcRn inhibitors)”
> “Participants already receiving CIDP treatment will have to discontinue their CIDP treatment before first IMP administration and must be willing to switch to the study IMP”
> “Has residual disability and active disease”

Source: [ClinicalTrials.gov NCT07091630](https://clinicaltrials.gov/study/NCT07091630)

<a id="topic-2.2.2.2-13"></a>

### Empasiprubart EMVIGORATE: population treated with intravenous immunoglobulin in the registry record

> “The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP.”
> “Has responded to IVIg in the past 5 years”
> “Receiving treatment with IVIg within a standard optimal maintenance dosing regimen, with a minimum weekly IVIg dose of at least 0.125 g/kg”

Source: [ClinicalTrials.gov NCT06920004](https://clinicaltrials.gov/study/NCT06920004)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
